| MeSH term | MeSH ID | Detail |
|---|---|---|
| Biliary Tract Neoplasms | D001661 | 7 associated lipids |
| Blepharitis | D001762 | 4 associated lipids |
| Blindness | D001766 | 6 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Bone Diseases | D001847 | 4 associated lipids |
| Bradycardia | D001919 | 13 associated lipids |
| Brain Diseases | D001927 | 27 associated lipids |
| Brain Edema | D001929 | 20 associated lipids |
| Bronchiolitis | D001988 | 6 associated lipids |
| Bronchiolitis Obliterans | D001989 | 8 associated lipids |
| Burkitt Lymphoma | D002051 | 15 associated lipids |
| Burns | D002056 | 34 associated lipids |
| Candidiasis, Oral | D002180 | 11 associated lipids |
| Candidiasis, Vulvovaginal | D002181 | 8 associated lipids |
| Carcinoma, Squamous Cell | D002294 | 14 associated lipids |
| Cardiomyopathy, Hypertrophic | D002312 | 6 associated lipids |
| Cardiomyopathy, Restrictive | D002313 | 1 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Carpal Tunnel Syndrome | D002349 | 3 associated lipids |
| Catalepsy | D002375 | 30 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Reduced incidence of acute, refractory acute, and chronic rejection after liver transplantation with FK506-based immunosuppression. European FK506 Multicentre Liver Study Group. | 1994 | Transplant. Proc. | pmid:7527960 | |
| Klintmalm GB et al. | Use of FK 506 for the prevention of recurrent allograft rejection after successful conversion from cyclosporine for refractory rejection. US Multicenter FK 506 Liver Study Group. | 1993 | Transplant. Proc. | pmid:7679826 |
| Fukuzawa M and Okada A | Analysis of mouse xenogeneic T-cell responses and the effect of FK 506 on these responses and on xeno-skin graft rejection. | 1994 | Transplant. Proc. | pmid:7513483 |
| Abou-Jaoude MM et al. | Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients. | 2003 | Transplant. Proc. | pmid:14612103 |
| Havrdova T et al. | Effect of tacrolimus versus cyclosporine on glucose metabolism of pancreas and kidney recipients in the late (> 8 years) posttransplant period. | 2011 | Transplant. Proc. | pmid:22099774 |
| Khalaf H et al. | Tacrolimus (FK 506) given three times daily after liver transplantation for minimizing nephrotoxicity and neurotoxicity. | 2003 | Transplant. Proc. | pmid:14612120 |
| Gamboa O et al. | Cost-effectiveness analysis of the early conversion of tacrolimus to mammalian target of rapamycin inhibitors in patients with renal transplantation. | 2011 | Transplant. Proc. | pmid:22099798 |
| Guitard J et al. | Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver transplant patients: a pilot study. | 2007 | Transplant. Proc. | pmid:17954189 |
| Warty VS et al. | Practical aspects of FK 506 analysis (Pittsburgh experience). | 1991 | Transplant. Proc. | pmid:1721259 |
| Park K et al. | Efficacy of tacrolimus in primary kidney transplant patients: multicenter, open-label prospective study. | 2000 | Transplant. Proc. | pmid:11119901 |
| Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
| Sher LS et al. | Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation. | 1996 | Transplant. Proc. | pmid:8623212 |
| Kumar MS et al. | ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. | 1998 | Transplant. Proc. | pmid:9636549 |
| Yu L et al. | Clinical experience with Prograf (tacrolimus, FK 506) in Chinese patients after renal transplantation. | 2000 | Transplant. Proc. | pmid:11119902 |
| Neylan JF | Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. | 1998 | Transplant. Proc. | pmid:9636551 |
| Gruessner RW et al. | Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. | 1998 | Transplant. Proc. | pmid:9532156 |
| Corry RJ et al. | Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. | 1998 | Transplant. Proc. | pmid:9532157 |
| Elmer DS et al. | Metabolic effects of FK 506 (tacrolimus) versus cyclosporine in portally drained pancreas allografts. | 1998 | Transplant. Proc. | pmid:9532159 |
| Wasserberg N et al. | Tacrolimus does not upregulate mucin gene expression after small bowel transplantation in rats. | 2003 | Transplant. Proc. | pmid:12644089 |
| Hayashi S et al. | Adenovirus-mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20). | 1997 | Transplant. Proc. | pmid:9193595 |
| Fernández A et al. | Complete switch to everolimus in long-term kidney transplants: evolution of the renal function. | 2009 Jul-Aug | Transplant. Proc. | pmid:19715915 |
| Alarcón-Zurita A et al. | Steroids withdrawal after 3 months of successful renal transplantation using a tacrolimus- and mycophenolate-based immunosuppression. | 2002 | Transplant. Proc. | pmid:11959216 |
| Ericzon BG et al. | Pancreaticoduodenal allotransplantation with FK 506 in the cynomolgus monkey. | 1990 | Transplant. Proc. | pmid:1689905 |
| Takada Y et al. | Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. | 2000 | Transplant. Proc. | pmid:10715416 |
| Land W et al. | Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. | 2001 | Transplant. Proc. | pmid:11406265 |
| McLachlan G et al. | Growth inhibition of the MOLT-4 human T-leukemia cell line. A comparison of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721291 |
| D'Silva M et al. | Immunosuppressive effect of brequinar on rat cardiac allograft survival in combination with leflunomide or FK 506. | 1996 | Transplant. Proc. | pmid:8623476 |
| Charco R et al. | Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. | 1998 | Transplant. Proc. | pmid:9636605 |
| Jang HJ et al. | Comparison of pancreas transplantation outcome between the cyclosporine and tacrolimus eras. | 2000 | Transplant. Proc. | pmid:11120249 |
| Squifflet JP et al. | The Benelux experience with the combination of tacrolimus and mycophenolate mofetil. | 1999 | Transplant. Proc. | pmid:10576050 |
| Tekgündüz E et al. | Electrolyte free water clearance could be an early sign of renal dysfunction in renal transplant patients. | 2009 | Transplant. Proc. | pmid:19917375 |
| Furlan V et al. | Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. | 1998 | Transplant. Proc. | pmid:9474996 |
| Zawiasa A et al. | Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus. | 2009 Jan-Feb | Transplant. Proc. | pmid:19249511 |
| Murase N et al. | Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. | 1994 | Transplant. Proc. | pmid:7518139 |
| Fujisaki S et al. | Effects of preformed antibodies induced by whole blood transfusion on small bowel transplantation. | 1994 | Transplant. Proc. | pmid:7518140 |
| Gaweco AS et al. | Common and sequential overexpression patterns of T-helper cytokines during acute (cellular) rejection, and correlation of proinflammatory cytokine expression with chronic (ductopenic) rejection of human liver allografts: a study under cyclosporine, FK 506, and quadruple BT 563 immunosuppression. | 1995 | Transplant. Proc. | pmid:7533370 |
| Tze WJ et al. | FK 506--an effective immunosuppressant in achieving long-term functional islet allograft survival in diabetic rats. | 1992 | Transplant. Proc. | pmid:1376509 |
| Rao PN et al. | Prediction of early graft function by effluent levels of hyaluronic acid in clinical liver transplantation. | 1993 | Transplant. Proc. | pmid:7682366 |
| Armstrong VW et al. | Metabolic liver function and lipoprotein metabolism after orthotopic liver transplantation in patients on immunosuppressive therapy with FK 506 or cyclosporine. | 1995 | Transplant. Proc. | pmid:7533371 |
| Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
| Kuriata-Kordek M et al. | The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. | 2003 | Transplant. Proc. | pmid:14529944 |
| Chiang Y et al. | Posttransplantation Kaposi sarcoma-experience in a patient receiving FK-506 and MMF. | 2003 | Transplant. Proc. | pmid:12591389 |
| Borrows R et al. | Tacrolimus monitoring in renal transplantation: a comparison between high-performance liquid chromatography and immunoassay. | 2005 | Transplant. Proc. | pmid:15919448 |
| Charco R et al. | Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy. | 2002 | Transplant. Proc. | pmid:12176478 |
| Laskow DA et al. | Phase II FK 506 multicenter concentration control study: one-year follow-up. | 1995 | Transplant. Proc. | pmid:7533431 |
| Yokoyama I et al. | Immunosuppressant effect on Fas antigen expression and p53 of an experimental tumor. | 1998 | Transplant. Proc. | pmid:9865346 |
| Reyes J et al. | Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721355 |
| Hossain MA et al. | Immunosuppression in auxiliary partial liver transplantation with FK506 in rats. | 1997 | Transplant. Proc. | pmid:9414861 |
| Bortman GV et al. | South American Heart Transplantation Registry of patients receiving everolimus in their immunosuppressive regimens. | 2010 Jan-Feb | Transplant. Proc. | pmid:20172342 |
| Parada MT et al. | Everolimus in lung transplantation in Chile. | 2010 Jan-Feb | Transplant. Proc. | pmid:20172343 |
| Forgacs B et al. | Successful conversion to rapamycin for calcineurin inhibitor-related neurotoxicity following liver transplantation. | 2005 | Transplant. Proc. | pmid:15919502 |
| Strassburg A et al. | Basiliximab reduces acute liver allograft rejection in pediatric patients. | 2002 | Transplant. Proc. | pmid:12270443 |
| Rifai K et al. | Severe hearing loss after liver transplantation. | 2005 | Transplant. Proc. | pmid:15919504 |
| Weimer R et al. | Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. | 2002 | Transplant. Proc. | pmid:12270445 |
| Miller J et al. | FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123008 |
| Yoshimura N et al. | Safety analysis following tacrolimus immunosuppression in renal transplant recipients in Japan: 3-year results in over 1000 patients. | 2002 | Transplant. Proc. | pmid:12176501 |
| Kilinç M et al. | FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report. | 2002 | Transplant. Proc. | pmid:12072309 |
| Toyama Y et al. | Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. | 1996 | Transplant. Proc. | pmid:8907924 |
| Takahashi K et al. | Successful results after 3 years' tacrolimus immunosuppression in ABO-incompatible kidney transplantation recipients in Japan. | 2002 | Transplant. Proc. | pmid:12176502 |
| Fahlke J et al. | Staggered immunosuppression with the interleukin-2 receptor antagonist daclizumab combined with tacrolimus, prednisolone, and mycophenolate mofetil after orthotopic liver transplantation: a pilot efficacy and safety study. | 2002 | Transplant. Proc. | pmid:12072328 |
| Yamada T et al. | Synergistic effect of FK 506 and trifluoperazine on the immunosuppression in rat small bowel transplantation. | 1996 | Transplant. Proc. | pmid:8907927 |
| De Paolis P et al. | "Immuknow" to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation. | 2011 | Transplant. Proc. | pmid:21620039 |
| Meçule A et al. | Interleukin-2 profiles shortly after tacrolimus conversion from a twice-daily to once-daily regimen. | 2011 | Transplant. Proc. | pmid:21620040 |
| Deuse T et al. | Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection? | 2007 | Transplant. Proc. | pmid:17362784 |
| Okano K et al. | Ameliorative effect of FK 506 on cold ischemia reperfusion injury of the rat liver. | 1994 | Transplant. Proc. | pmid:7520635 |
| Thomson AW et al. | Immunosuppressive activity, T-cell subset analysis, and acute toxicity of FK-506 in rats. | 1989 | Transplant. Proc. | pmid:2468203 |
| Hossein-Nia M et al. | Urinary proteins as a marker of drug-induced renal damage following treatment with cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721388 |
| Shapiro R et al. | Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. | 1997 | Transplant. Proc. | pmid:9290809 |
| Kumano K et al. | Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. | 1997 Feb-Mar | Transplant. Proc. | pmid:9123293 |
| Braun F et al. | Pharmacokinetics of tacrolimus primary immunosuppression in kidney transplant recipients. | 2001 | Transplant. Proc. | pmid:11377473 |
| Wilczek HE et al. | Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). | 1996 | Transplant. Proc. | pmid:8962232 |
| Saito K et al. | Study of pharmacokinetic parameters of tacrolimus by different oral administration periods in renal transplantation. | 2002 | Transplant. Proc. | pmid:12176553 |
| Toraishi T et al. | Falsely abnormally elevated blood trough concentration of tacrolimus measured by antibody-conjugated magnetic immunoassay in a renal transplant recipient: a case report. | 2012 | Transplant. Proc. | pmid:22310597 |
| Reutzel-Selke A et al. | Donor pretreatment of grafts from marginal donors improves long-term graft outcome. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267150 |
| Ettenger R | The practical problems of prednisone in pediatric renal transplantation. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267159 |
| Masaoka T et al. | Phase II study of FK 506 for allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721417 |
| Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
| Yuzawa K et al. | Topical immunosuppression in skin grafting with FK 506 ointment. | 1996 | Transplant. Proc. | pmid:8658707 |
| Takahashi Y et al. | Pharmacokinetic Profile of Twice- and Once-daily Tacrolimus in Pediatric Kidney Transplant Recipients. | Transplant. Proc. | pmid:28104153 | |
| Yagura K et al. | Pharmacokinetic characteristics of two types of liposomal FK 506. | 1996 | Transplant. Proc. | pmid:8658708 |
| Shi Y et al. | Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. | Transplant. Proc. | pmid:28104150 | |
| Rayes N et al. | Distribution of lymphocyte subtypes in liver transplant recipients with viral reinfection or de novo malignancy. | 1998 | Transplant. Proc. | pmid:9723303 |
| Boletis J et al. | Delayed renal graft function: the influence of immunosuppression. | 2005 | Transplant. Proc. | pmid:15964337 |
| Reggiani P et al. | Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. | 1998 | Transplant. Proc. | pmid:9723308 |
| Levy GA | Neoral use in the liver transplant recipient. | 2000 | Transplant. Proc. | pmid:10814745 |
| Russ GR et al. | Reduced and standard target concentration tacrolimus with sirolimus in renal allograft recipients. | 2003 | Transplant. Proc. | pmid:12742480 |
| Ciancio G et al. | Effect of daclizumab, tacrolimus, and mycophenolate mofetil in pediatric first renal transplant recipients. | 2002 | Transplant. Proc. | pmid:12176637 |
| Rayhill SC et al. | A cyclosporine-based immunosuppressive regimen may be better than tacrolimus for long-term liver allograft survival in recipients transplanted for hepatitis C. | 2006 | Transplant. Proc. | pmid:17175350 |
| Nojima M et al. | Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function. | Transplant. Proc. | pmid:28104155 | |
| Mueller AR et al. | Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. | 2001 Feb-Mar | Transplant. Proc. | pmid:11267321 |
| Percy C et al. | Impact of Acute Infection Requiring Hospitalization on Tacrolimus Blood Levels in Kidney Transplant Recipients. | 2017 | Transplant. Proc. | pmid:29149962 |
| Yumiba T et al. | Immunosuppressive and diabetogenic effect of FK 506 on pancreatic islet xenotransplantation. | 1995 | Transplant. Proc. | pmid:7540780 |
| Krämer BK et al. | Efficacy of Prolonged- and Immediate-release Tacrolimus in Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. | 2017 | Transplant. Proc. | pmid:29149958 |
| Nikolaidis NL et al. | Metabolic effects of FK 506 in patients with severe psoriasis: short-term follow-up of seven cases. | 1991 | Transplant. Proc. | pmid:1721450 |
| Cofan F et al. | Fatty acid composition in low-density lipoproteins from renal transplant recipients. | 1999 | Transplant. Proc. | pmid:10500603 |
| Ochiai T et al. | Studies on FK506 in experimental organ transplantation. | 1988 | Transplant. Proc. | pmid:2450414 |
| Uemoto S et al. | Safety and efficacy of once-daily modified-release tacrolimus in liver transplant recipients: a multicenter postmarketing surveillance in Japan. | 2014 | Transplant. Proc. | pmid:24767340 |
| GarcÃa-Bello JA et al. | Effect of Immunosuppressive Therapy on Cardiovascular Risk Factor Prevalence in Kidney-Transplanted Children: Comparative Study. | 2016 | Transplant. Proc. | pmid:27110020 |
| Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
| Braun F et al. | Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. | 1998 | Transplant. Proc. | pmid:9636496 |